KRTX — Karuna Therapeutics Share News
0.000.00%
Last trade - 00:00- $12.58bn
- $11.32bn
- $0.65m
U.S. STOCKS ON THE MOVE-Cue Health, Charles Schwab, Semtech
U.S. STOCKS ON THE MOVE-Franchise Group, Connect Biopharma, OSI Systems
Karuna Therapeutics falls on hypertension concerns for schizophrenia drug
U.S. STOCKS ON THE MOVE-WestRock, PacWest, Foot Locker
U.S. STOCKS ON THE MOVE-Crypto stocks, gold miners, Karuna Therapeutics
Karuna Therapeutics up 19% as schizophrenia drug meets main goal in late-stage trial
Karuna's schizophrenia drug meets main goal in late-stage trial (updated)
Karuna's schizophrenia drug meets main goal in late-stage trial
Brief: Karuna Therapeutics Says Positive Results From Phase 3 Emergent-3 Trial Of KarXT In Schizophrenia
Brief: Karuna Therapeutics Maintains Less Than $1 Mln In Excess Of FDIC Standard Deposit Insurance Limit With SVB
Brief: Karuna Therapeutics reports Q4 net loss per share of USD 2.22
Karuna Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Karuna Therapeutics Reports Fourth Quarter 2022 Financial Result
Karuna Therapeutics Inc expected to post a loss of $2.25 a share - Earnings Preview
Brief: Karuna Therapeutics Announces Global License Agreement
U.S. RESEARCH ROUNDUP- Apollo Global Management, Microsoft, ServiceNow
Biotech enters new year with worst days behind - Mizuho
Biotech enters new year with worst days behind - Mizuho
Karuna Therapeutics appoints new CEO, shares slide